MINOLIRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINOLIRA (MINOLIRA).
Sodium-glucose co-transporter-2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9, UGT2B4, and UGT1A1; minor metabolism via CYP enzymes (CYP3A4, CYP2C8). |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 25%; the remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | ~85% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5–0.8 L/kg, suggesting moderate tissue distribution. |
| Bioavailability | Oral: 70–80% (first-pass metabolism reduces absolute bioavailability to ~75%). |
| Onset of Action | Oral: 1–2 hours; Intravenous: within 5–10 minutes. |
| Duration of Action | Oral: 8–12 hours for therapeutic effect; Intravenous: 4–6 hours post-infusion. |
60 mg subcutaneously once daily
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), reduce dose to 30 mg subcutaneously once daily. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-to-severe hepatic impairment (Child-Pugh B or C), reduce dose to 30 mg subcutaneously once daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function in elderly as age-related decline may necessitate dose reduction. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINOLIRA (MINOLIRA).
| Breastfeeding | Excreted in human milk; milk-to-plasma ratio approximately 0.5-0.8. Concentrations in breastfed infants are low but may cause infant tooth discoloration and bone growth inhibition. The American Academy of Pediatrics considers minocycline compatible with breastfeeding; however, alternative antibiotics are preferred, especially in neonates. |
| Teratogenic Risk | MINOLIRA (minocycline) is contraindicated in pregnancy. First trimester: Associated with central nervous system anomalies, including neural tube defects and hydrocephalus, and cardiovascular malformations. Second/third trimester: Causes reversible inhibition of fetal bone growth and permanent tooth discoloration (yellow-gray-brown). Risk of maternal hepatotoxicity and pancreatitis is increased during pregnancy. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["History of serious hypersensitivity reaction to MINOLIRA","Severe renal impairment (eGFR < 30 mL/min/1.73 m²)","End-stage renal disease or dialysis","Pregnancy (second and third trimester)","Lactation"]
| Precautions | ["Ketoacidosis (including euglycemic ketoacidosis)","Acute kidney injury and need for monitoring of renal function","Volume depletion, hypotension, and electrolyte abnormalities","Urosepsis and pyelonephritis","Lower limb amputation (increased risk with prior amputation, peripheral vascular disease, neuropathy)","Genital mycotic infections"] |
Loading safety data…
| Fetal Monitoring | Maternal: Liver function tests (AST, ALT, bilirubin), renal function, and complete blood count (due to risk of neutropenia and thrombocytopenia). Fetal: Ultrasound for fetal growth and development if inadvertent exposure occurs. Neonatal: Observe for hyperbilirubinemia and kernicterus (due to displacement of bilirubin from albumin). |
| Fertility Effects | Minocycline may impair female fertility by inhibiting implantation and trophoblast growth in animal studies. Human data are limited but suggest potential reversible effects on ovulation and spermatogenesis. Caution in couples attempting conception; use effective contraception during therapy. |